Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is complete-response-letter deficiency list after a CRL citing manufacturing, not efficacy. Regulatory-affairs lead in a safety team sitting on a new disproportionate signal has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. A CRL citing manufacturing, not efficacy is noise around an already-controlled CMC and Development Pathways process in a safety team sitting on a new disproportionate signal, given complete-response-letter deficiency list. 2. A CRL citing manufacturing, not efficacy is the event in complete-response-letter deficiency list that forces Proceed under protocol for regulatory-affairs lead under Pharma & Life Sciences. 3. Complete-response-letter deficiency list shows a one-file miss after a CRL citing manufacturing, not efficacy, not a CMC and Development Pathways program failure. 4. Complete-response-letter deficiency list cannot decide to drop a secondary yet after a CRL citing manufacturing, not efficacy; hold is the only Pharma & Life Sciences close a safety team sitting on a new disproportionate signal can defend.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a CRL citing manufacturing, not efficacy. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read complete-response-letter deficiency list against a CRL citing manufacturing, not efficacy and write the one fact that would move to drop a secondary for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (complete-response-letter deficiency list after a CRL citing manufacturing, not efficacy). If complete-response-letter deficiency list cannot force a Pharma & Life Sciences label under CMC and Development Pathways, stop. If complete-response-letter deficiency list after a CRL citing manufacturing, not efficacy cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences CMC and Development Pathways close, regulatory-affairs lead must state the unresolved clinical or safety evidence requirement explicitly.